They demonstrated sustained in vitro tumor cell killing by γδ CAR-iT-cells in the presence of IL-15, with markedly less IFN-γ and other inflammatory cytokines being produced compared to conventional αβ CAR-T-cells, potentially resulting in lower risk of CRS. The gene discussed is IL15; the disease is congenital rubella syndrome.